Tag: NSAID
NSAID (nonsteroidal anti-inflammatory drug): A type of pain medication that acts by blocking the action of COX enzymes, which produce prostaglandins that promote inflammation, pain, and fever. Over-the-counter NSAIDs include aspirin, ibuprofen (Advil, Motrin) and naproxen (Aleve). The best known prescription NSAID is celecoxib (Celebrex).
Articles
News
- 04/18/15
- Aspirin reduces growth and self-renewal capacity of BC stem cells
- 08/10/14
- Aspirin use is linked to improved breast cancer survival
- 11/21/11
- Use of NSAIDs before diagnosis does not improve BC survival
- 07/11/11
- Taking Celebrex might reduce effectiveness of chemotherapy
- 04/28/11
- Aspirin linked to reduced BC risk, but ibuprofen may increase it
Studies
-
Acetyl salicylic acid, COX-2 inhibitors and other NSAIDs and breast cancer survival in a Finnish population-based cohort
Cite
Malin M, Murto M, Arponen O, Siltari A, Artama M, Visvanathan K, et al. Acetyl salicylic acid, COX-2 inhibitors and other NSAIDs and breast cancer survival in a Finnish population-based cohort. Authorea, Inc.; 2024; 10.22541/au.172549517.74928122/v1
-
Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells
Cite
Arzuk E, Birim D, Armağan G. Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells. Naunyn-Schmiedeberg's Archives of Pharmacology. Springer Science and Business Media LLC; 2024; 10.1007/s00210-024-03286-2
-
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer
Cite
Qian X, Yang H, Ye Z, Gao B, Qian Z, Ding Y, et al. Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. ACS Nano. American Chemical Society (ACS); 2024; 10.1021/acsnano.4c02947
-
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
Cite
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, et al. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. American Medical Association (AMA); 2024; 10.1001/jama.2024.4840
-
Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis
Cite
Baker A, Kartsonaki C. Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis. The Oncologist. Oxford University Press (OUP); 2023; 10.1093/oncolo/oyad186
-
Abstract P4-03-02: Low-dose aspirin prescriptions and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up
Cite
Solmunde E, Pedersen RN, Nørgaard M, Mellemkjær L, Friis S, Ejlertsen B, et al. Abstract P4-03-02: Low-dose aspirin prescriptions and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P4-03-02-P4-03-02 10.1158/1538-7445.sabcs22-p4-03-02
-
Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort
Cite
Sherman ME, Vierkant RA, Masters M, Radisky DC, Winham SJ, Degnim AC, et al. Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort. Cancer Prevention Research. American Association for Cancer Research (AACR); 2023; 10.1158/1940-6207.capr-22-0403
-
Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy
Cite
Johns C, Cauble M, Liu Y, Rahimi A, Alluri P, Nwachukwu C, et al. Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2022; 114:e5 10.1016/j.ijrobp.2022.07.683
-
Abstract P2-11-01: Breast cancer (BC) risk among patients with benign breast disease (BBD) by NSAID use
Cite
Vierkant RA, Masters M, Teras LR, Sherman ME. Abstract P2-11-01: Breast cancer (BC) risk among patients with benign breast disease (BBD) by NSAID use. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P2-11-01-P2-11-01 10.1158/1538-7445.sabcs21-p2-11-01
-
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
Cite
Chen WY, Ballman KV, Winer EP, Openshaw TH, Hahn OM, Briccetti FM, et al. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:360922-360922 10.1200/jco.2022.40.36_suppl.360922
-
Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination
Cite
McCormick PJ, Assel M, Van Zee KJ, Vickers AJ, Nelson JA, Morrow M, et al. Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 28:5134-5140 10.1245/s10434-021-09722-4
-
Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer
Cite
Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I. Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Research and Treatment; 2021; 10.1007/s10549-021-06229-0
-
Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women
Cite
Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A. Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2021; 30:643-652 10.1158/1055-9965.epi-20-1292
-
Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019
Cite
Ma S, Guo C, Sun C, Han T, Zhang H, Qu G, et al. Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.02.005
-
Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy
Cite
Sherman ME, Vierkant RA, Kaggal S, Hoskin TL, Frost MH, Denison L, et al. Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. Cancer Prevention Research. American Association for Cancer Research (AACR); 2020; 13:967-976 10.1158/1940-6207.capr-20-0178
-
Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women
Cite
Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01343-1
-
Aspirin use and risk of breast cancer in African American women
Cite
Bertrand KA, Bethea TN, Gerlovin H, Coogan PF, Barber L, Rosenberg L, et al. Aspirin use and risk of breast cancer in African American women. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01335-1
-
Effect of aspirin on cancer incidence and mortality in older adults
Cite
McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, et al. Effect of aspirin on cancer incidence and mortality in older adults. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 10.1093/jnci/djaa114
-
Abstract P5-08-06: NSAID use and breast cancer risk in a retrospective cohort of women with benign breast disease
Cite
Degnim A, Vierkant R, Winham S, Frost M, Visscher D, Carter J, et al. Abstract P5-08-06: NSAID use and breast cancer risk in a retrospective cohort of women with benign breast disease. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p5-08-06
-
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population‐based study
Cite
Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, et al. Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population‐based study. Cancer. Wiley; 2019; 125:3836-3844 10.1002/cncr.32364
-
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study
Cite
Kehm RD, Hopper JL, John EM, Phillips K, MacInnis RJ, Dite GS, et al. Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1135-y
-
No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study
Cite
Frisk G, Ekberg S, Lidbrink E, Eloranta S, Sund M, Fredriksson I, et al. No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-1065-0
-
Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study
Cite
Bens A, Friis S, Dehlendorff C, Jensen M, Ejlertsen B, Kroman N, et al. Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. Preventive Medicine. Elsevier BV; 2018; 116:186-193 10.1016/j.ypmed.2018.09.015
-
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27
Cite
Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, et al. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:1003-1008 10.1093/jnci/djy017
-
The impact of aspirin use on breast cancer subtype and clinical course
Cite
Williams AD, Li YR, So A, Steel L, Carrigan E, Ro V, et al. The impact of aspirin use on breast cancer subtype and clinical course. Journal of Surgical Research. Elsevier BV; 2018; 230:71-79 10.1016/j.jss.2018.04.040
-
Nonsteroidal anti‐inflammatory drug use and breast cancer risk in a European prospective cohort study
Cite
Cairat M, Fournier A, Murphy N, Biessy C, Scalbert A, Rinaldi S, et al. Nonsteroidal anti‐inflammatory drug use and breast cancer risk in a European prospective cohort study. International Journal of Cancer. Wiley; 2018; 143:1688-1695 10.1002/ijc.31570
-
The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells
Cite
Ma Q, Gao Y, Wei D, Jiang N, Ding L, He X, et al. The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells. Ultrastructural Pathology. Informa UK Limited; 2018; 42:289-294 10.1080/01913123.2018.1459996
-
Pre-diagnostic aspirin use and mortality after breast cancer
Cite
Wang T, Parada H, McClain KM, Bradshaw PT, Terry MB, Teitelbaum SL, et al. Pre-diagnostic aspirin use and mortality after breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2018; 29:417-425 10.1007/s10552-018-1020-5
-
Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity
Cite
Huang C, Chen Y, Liu H, Yang J, Song X, Zhao J, et al. Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget. Impact Journals, LLC; 2017; 8:115254-115269 10.18632/oncotarget.23250
-
Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals
Cite
Dandah O, Najafzadeh M, Isreb M, Linforth R, Tait C, Baumgartner A, et al. Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. Elsevier BV; 2018; 826:41-46 10.1016/j.mrgentox.2017.12.001
-
Abstract 3012: Long-term aspirin use and total and cancer-specific mortality
Cite
Cao Y, Stampfer M, Willett W, Spiegelman D, Manson J, Rimm E, et al. Abstract 3012: Long-term aspirin use and total and cancer-specific mortality. Epidemiology. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-3012
-
Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan
Cite
Yang Y, Kornelius E, Chiou J, Lai Y, Lo S, Peng C, et al. Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. Journal of Women's Health. Mary Ann Liebert Inc; 2017; 26:1278-1284 10.1089/jwh.2016.6040
-
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway
Cite
Liu B, Yan S, Qu L, Zhu J. Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway. Cancer Cell International. Springer Science and Business Media LLC; 2017; 17 10.1186/s12935-016-0378-2
-
Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients
Cite
Shiao J, Thomas KM, Rahimi AS, Rao R, Yan J, Xie X, et al. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:463-471 10.1007/s10549-016-4081-8
-
The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size
Cite
Simonsson M, Björner S, Markkula A, Nodin B, Jirström K, Rose C, et al. The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. International Journal of Cancer. Wiley; 2016; 140:163-175 10.1002/ijc.30432
-
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study
Cite
Dierssen-Sotos T, Gómez-Acebo I, de Pedro M, Pérez-Gómez B, Servitja S, Moreno V, et al. Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2692-4
-
Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Cite
Bradley MC, Black A, Freedman AN, Barron TI. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. Wiley; 2016; 122:2067-2075 10.1002/cncr.30004
-
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies
Cite
Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, et al. Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0152402 10.1371/journal.pone.0152402
-
Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis
Cite
Negi AK, Bhatnagar A, Agnihotri N. Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis. Biomedicine & Pharmacotherapy. Elsevier BV; 2016; 79:9-16 10.1016/j.biopha.2016.01.032
-
Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator
Cite
Yin T, Wang G, Ye T, Wang Y. Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep19534
-
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Cite
Zelenay S, van der Veen A, Böttcher J, Snelgrove K, Rogers N, Acton S, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. Elsevier BV; 2015; 162:1257-1270 10.1016/j.cell.2015.08.015
-
Piroxicam, a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation
Cite
Rai N, Sarkar M, Raha S. Piroxicam, a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation. Pharmacological Reports. Springer Science and Business Media LLC; 2015; 67:1215-1223 10.1016/j.pharep.2015.05.012
-
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition
Cite
Maity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Laboratory Investigation. Springer Science and Business Media LLC; 2015; 95:702-717 10.1038/labinvest.2015.49
-
Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis
Cite
Huang X, Gao P, Sun J, Song Y, Tsai C, Liu J, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes & Control. Springer Science and Business Media LLC; 2015; 26:589-600 10.1007/s10552-015-0539-y
-
Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis
Cite
de Pedro M, Baeza S, Escudero M, Dierssen-Sotos T, Gómez-Acebo I, Pollán M, et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 149:525-536 10.1007/s10549-015-3267-9
-
NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin–Aromatase Interactions
Cite
Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, et al. NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin–Aromatase Interactions. Cancer Research. American Association for Cancer Research (AACR); 2014; 74:4446-4457 10.1158/0008-5472.can-13-3603
-
Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women
Cite
Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Cai H, Fair AM, et al. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 146:439-446 10.1007/s10549-014-3030-7
-
Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery
Cite
Forget P, Bentin C, Machiels J, Berliere M, Coulie P, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. British Journal of Anaesthesia. Elsevier BV; 2014; 113:i82-i87 10.1093/bja/aet464
-
Initiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy
Cite
Holmes CE, Jasielec J, Levis JE, Skelly J, Muss HB. Initiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy. Clinical and Translational Science. Wiley; 2013; 6:386-390 10.1111/cts.12070
-
Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer Model
Cite
Na Y, Yoon Y, Son D, Seok S. Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer Model. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e63451 10.1371/journal.pone.0063451
-
Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics?
Cite
Forget P, Simonet O, De Kock M. Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics?. F1000Research. F1000 Research Ltd; 2013; 2:102 10.12688/f1000research.2-102.v1
-
Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells
Cite
YAN F, HE Q, HU X, LI W, WEI K, LI L, et al. Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells. Molecular Medicine Reports. Spandidos Publications; 2013; 7:909-914 10.3892/mmr.2013.1257
-
Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells
Cite
JEON Y, SUH YJ. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncology Reports. Spandidos Publications; 2012; 29:819-825 10.3892/or.2012.2158
-
Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence
Cite
Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3468-3477 10.1200/jco.2012.42.2006
-
Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study
Cite
Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2010; 21:1503-1512 10.1007/s10552-010-9579-5
-
NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals
Cite
Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. ACS Medicinal Chemistry Letters. American Chemical Society (ACS); 2012; 3:257-262 10.1021/ml300002m
-
Naproxen aggravates doxorubicin-induced cardiomyopathy in rats
Cite
Pathan R, Singh B, Pillai K, Dubey K. Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. Indian Journal of Pharmacology. Medknow; 2010; 42:44 10.4103/0253-7613.62411
-
Use of Nonsteroidal Anti-inflammatory Drugs and Survival Following Breast Cancer Diagnosis
Cite
Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, et al. Use of Nonsteroidal Anti-inflammatory Drugs and Survival Following Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 21:239-242 10.1158/1055-9965.epi-11-1012
-
Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells
Cite
El-Awady RA, Saleh EM, Ezz M, Elsayed AM. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicology and Applied Pharmacology. Elsevier BV; 2011; 255:271-286 10.1016/j.taap.2011.06.019
-
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype
Cite
Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes & Control. Springer Science and Business Media LLC; 2011; 22:965-975 10.1007/s10552-011-9769-9
-
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study
Cite
Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:149-155 10.1007/s10549-010-1074-x
-
Do Intraoperative Analgesics Influence Breast Cancer Recurrence After Mastectomy? A Retrospective Analysis
Cite
Forget P, Vandenhende J, Berliere M, Machiels J, Nussbaum B, Legrand C, et al. Do Intraoperative Analgesics Influence Breast Cancer Recurrence After Mastectomy? A Retrospective Analysis. Anesthesia & Analgesia. Ovid Technologies (Wolters Kluwer Health); 2010; 110:1630-1635 10.1213/ane.0b013e3181d2ad07
-
Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis
Cite
Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:627-637 10.1093/jnci/djq101
-
Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women
Cite
Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1033-1041 10.1158/1055-9965.epi-09-0975
-
Aspirin Intake and Survival After Breast Cancer
Cite
Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin Intake and Survival After Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1467-1472 10.1200/jco.2009.22.7918
-
Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model
Cite
Tran-Thanh D, Buttars S, Wen Y, Wilson C, Done SJ. Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model. Cancer Prevention Research. American Association for Cancer Research (AACR); 2010; 3:202-211 10.1158/1940-6207.capr-09-0181
-
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study
Cite
Gierach GL, Lacey JV, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study. Breast Cancer Research. Springer Science and Business Media LLC; 2008; 10 10.1186/bcr2089
-
Antibiotic Use in Relation to the Risk of Breast Cancer
Cite
Velicer CM. Antibiotic Use in Relation to the Risk of Breast Cancer. JAMA. American Medical Association (AMA); 2004; 291:827 10.1001/jama.291.7.827
-
Effect of Red Clover Isoflavones on Cox-2 Activity in Murine and Human Monocyte/Macrophage Cells
Cite
Lam ANC, Demasi M, James MJ, Husband AJ, Walker C. Effect of Red Clover Isoflavones on Cox-2 Activity in Murine and Human Monocyte/Macrophage Cells. Nutrition and Cancer. Informa UK Limited; 2004; 49:89-93 10.1207/s15327914nc4901_12